Alzheimer's Disease Progression Slowed by New FDA-Approved Drug

A Major Breakthrough in Treating Alzheimer's Disease

In an unprecedented stride for Alzheimer's research, the U.S. Food and Drug Administration (FDA) has approved Kisunla, a pioneering drug by Eli Lilly that curbs cognitive decline in early or mild dementia cases caused by Alzheimer's Disease. This constitutes a beacon of hope for patients in initial stages and their families.

Second Drug to Slow Cognitive Deterioration

Kisunla's endorsement marks it as the second drug with strong evidence to inhibit cognitive decline, trailing after a similar drug approved last year by Japanese firm Eisai. The value of these drugs, which adds approximately seven months to cognitive health, is weighed against potential side effects, such as brain swelling.

Struggles and Breakthroughs in Alzheimer's Treatment

This approval signifies a huge breakthrough in Alzheimer's treatment, following years of fruitless clinical trials. Yet, it also sparks questions about who should receive such treatments and how long they relay benefits. The costs of the drug will vary, with a year's worth of therapy amounting to £25,256.

The Science Behind Kisunla

Kisunla, known chemically as donanemab, was awarded approval based on the results of an exhaustive 18-month study. The study reported approximately 22% slower cognitive decline in patients who received treatment than those under placebo infusion. However, it is also noteworthy that the rates of brain swelling and bleeding, common to all plaque-targeting drugs, were slightly higher in the Kisunla study compared to its competitor, Leqembi.

For more information and the latest updates, click here to explore more on Google News.